Monopar Therapeutics (MNPR) surges 20% pre-market after entering exclusive agreement with Alexion, AstraZeneca for Wilson ...

Monopar Therapeutics' market value nearly tripled Thursday after the biotechnology company agreed to license a treatment for patients with a rare genetic condition from AstraZeneca unit Alexion.

Sino-America clinical-stage biotech Eccogene announced that it will receive a $60 million payment from AstraZeneca, which is ...

AstraZeneca, a global biopharmaceutical company that develops and commercializes prescription medicines, became a household ...

Monopar Therapeutics shares rose after the biotechnology company agreed to license a treatment for patients with a rare genetic condition from AstraZeneca unit Alexion. Shares of the Wilmette, Ill., ...

The shortlisted teams in the learning and development category larger organisations category of the Personnel Today Awards ...

The Bcl-2 inhibitor venetoclax is highly effective and is another first- or second-line option even if this agent, like BTK inhibitors, also appears to require continuous dosing, said Stadtmauer, ...

The first thing Promise Bio CEO Ronel Veksler wants you to know about the biotech company he co-founded is that it's not ...

Ionis has five FDA-approved drugs and promising upcoming approvals. See more about IONS stock and why it warrants a Buy ...

Under the terms of the license agreement, Monopar will pay Alexion an upfront in the form of a cash payment and equity in Monopar. Future payments are based on tiered royalties on net sales and ...

Plus: Groupon cofounder’s healthcare venture, investments in CAR-T therapies and the upcoming Forbes Healthcare Summit.